更全面的创业板投资标尺

Group 1 - The article emphasizes the balanced layout of A-share innovative and growth-oriented companies, focusing on the "Three Innovations and Four New" positioning of the ChiNext board, which has seen a steady increase in the number of listed companies since its inception, reaching 1,390 stocks with a total market value of 16.49 trillion RMB as of November 21, 2025, and an average daily trading volume of 523 billion RMB in the past month [1][3][41] - Continuous policy support is highlighted, with a significant number of "specialized, refined, characteristic, and innovative" small giant companies, totaling 1,117, of which 420 are listed on the ChiNext, accounting for 37.60% of the total [1][10][41] - Institutional funds show high interest, with the total market value of ChiNext component stocks held by actively managed equity funds showing an upward trend, exceeding 17% in recent years, and ChiNext-related ETFs have seen substantial growth, with the latest share exceeding 800 million and total scale surpassing 170 billion RMB [1][14][15][41] Group 2 - The ChiNext Composite Index (399102.SZ) encompasses all stocks listed on the ChiNext, reflecting the overall price changes and market trends, with a smaller average market capitalization of 13.034 billion RMB compared to the ChiNext Index and ChiNext 50 [19][22][42] - The industry concentration is low, with a more balanced allocation across high-growth innovative sectors, including new energy, electronics, pharmaceuticals, and computing, compared to the more concentrated distribution in the ChiNext 50 and ChiNext Index [26][42] - Valuation is at a low level, with a price-to-earnings ratio of 62.64 and a price-to-book ratio of 4.04, both below historical median levels, and a forecasted compound annual growth rate of net profit of 39.92% over the next two years, outperforming the ChiNext Index and ChiNext 50 [30][33][42] - The risk-return profile of the ChiNext Composite Index is notable, with an annualized return of 8.99% since the base period and a Sharpe ratio of 0.44, indicating superior performance and risk characteristics compared to the ChiNext Index and ChiNext 50 [38][42]